RUNX2 and breast cancer: Our results show that BC cells treated with CADD522 exerted significant inhibition in glucose consumption, indicating that cells treated with CADD522 might be exposed to glucose deprived conditions that could delay cell cycle progression and reduce RUNX2-DNA binding.